Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Quanlin Guan has a total of 144 co-authors. Here are the top co-authors by number of shared publications:

  • Fei Su

    The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, PR China; Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu, PR China

    7 shared publications
  • Yandong Miao

    Cancer Center, Yantai Affiliated Hospital of Binzhou Medical University, The 2nd Medical College of Binzhou Medical University, Yantai, China

    4 shared publications
  • Hong-Xin Su

    Lanzhou Univ, Hosp 1, Dept Oncol, Lanzhou 730000, Gansu, Peoples R China

    3 shared publications
  • Hui Qiao

    Department of Oncology Surgery the First Hospital of Lanzhou University Lanzhou China

    3 shared publications
  • Jiang Wu

    The First Clinical Medical College of Lanzhou University, Lanzhou, China

    3 shared publications
  • Qianwen Luo

    The First Clinical Medical College of Lanzhou University, Lanzhou, China

    3 shared publications

Latest Publications

  • Open Access

    Lattice radiotherapy boost integrated with thoracic VMAT in bulky stage IIIB non–small cell lung cancer: a case report

    by Song Wang, Xing-Chuan Li, Jun-Tao Ran, Quan-Lin Guan

    Background: Bulky unresectable stage III non-small cell lung cancer (NSCLC) presents a clinical challenge during definitive radiotherapy, as homogeneous dose escalation is often constrained by organ-at-risk (OAR) tolerance. Spatially fractionated radiotherapy (SFRT), including lattice radiotherapy (LRT), creates an intratumoral peak-valley dose distribution and may provide a means to intensify local dose delivery. However, the optimal dose, fractionation, vertex geometry, treatment sequence, and contribution of LRT to clinical response remain uncertain. Case presentation: We report a 41-year-old never-smoking Han Chinese man with bulky unresectable stage IIIB (cT4N2M0, AJCC 8th edition) disease, with a primary tumor measuring 71×53 mm at baseline. After two cycles of induction platinum-based chemotherapy, the disease was classified as stable disease. The patient subsequently received thoracic VMAT to 60 Gy in 15 fractions, during this course, a LRT plan was interleaved within the VMAT plan and delivered using an interleaved “4 VMAT treatments plus 1 LRT per week” pattern. Sixteen spheres were placed within the gross tumor volume (GTV), achieving a peak-to-valley dose ratio (PVDR) of 3.52. Serial CT showed a reduction in the sum of lesion diameters (SOD) of 20.7% after eight VMAT fractions, 29.6% after 14 fractions, and 40% at the 2-month post-treatment assessment. The patient developed grade 4 hematologic toxicity and grade 1 radiation pneumonitis after additional systemic therapy. Conclusion: This case demonstrates the delivery of weekly LRT during thoracic VMAT in a patient with bulky stage IIIB NSCLC, with significant tumor regression observed. This approach should be regarded as technically feasible in this case only, rather than as evidence that LRT can circumvent OAR (organs at risk) constraints or improve tumor control.

  • Open Access

    Unraveling tumor cell heterogeneity and epithelial-mesenchymal plasticity in gastric adenocarcinoma: an integrative multi-omics framework evaluating PVR/CD155 as a tumor cell-intrinsic EMT-associated target

    by Jianwen Li, Zitong Qin, Ting Wang, Weiping Li, Jinmin Ma, Quanlin Guan

    Background: The tumor microenvironment (TME) of gastric adenocarcinoma is exceptionally heterogeneous, and epithelial-mesenchymal transition (EMT) is a central mechanism promoting local invasion and metastatic spread. Even so, how EMT-programmed cells are spatially arranged within tumor tissue, how they interact with neighboring immune populations, and which molecular nodes might be exploited therapeutically remain incompletely defined. Methods: We built a large-scale, multi-layered analytical pipeline that combined single-cell transcriptomics (approximately 250,000 cells drawn from two independent patient cohorts), Visium-based spatial transcriptomics processed through Bayesian cell2location deconvolution, niche-level SpaTopic modeling, deep-learning histology analysis (ResNet50 feature extraction paired with CellProfiler-derived morphometrics), and ensemble survival modeling spanning over one hundred algorithmic combinations. Gaussian mixture modeling was used to define EMT-high cell states, the Scissor framework was applied to link fibroblast subsets to patient mortality, and a multi-tier filtering scheme was used to nominate druggable candidate genes. The top candidate, PVR/CD155, was interrogated experimentally by RT-qPCR, Western blotting, immunohistochemistry, and siRNA knockdown in AGS cells. We further evaluated PVR druggability by molecular docking, a 100-nanosecond molecular dynamics trajectory, and MM/GBSA binding-energy estimation using PP-121 as a candidate ligand. Results: Sub-clustering identified seven fibroblast subclusters: Fib_APOD, Fib_COL4A1, Fib_SLPI, Fib_COL1A1, Fib_CCL4, Fib_STMN1, and Fib_S100B. The SLPI-high subset preferentially localized to peritoneal metastases. Phenotype-guided Scissor mapping nominated a survival-associated fibroblast program enriched within COL4A1-expressing fibroblast states. PVR/CD155 was prioritized as an EMT-linked candidate gene; single-cell expression profiling showed that PVR was most frequently detected in endothelial, epithelial and fibroblast compartments, with low detection in lymphoid and plasma cells. PVR/CD155 was significantly upregulated in gastric cancer cell lines and tumor tissues. PVR/CD155 knockdown in AGS cells decreased proliferation, migration and invasion, supporting a tumor cell-intrinsic functional role rather than establishing PVR as a stromal immune biomarker. Molecular docking and dynamics simulations identified PP-121 as a candidate PVR-binding ligand for future biochemical validation. Conclusion: The proposed framework connects single-cell resolution with spatial and histological data, produces validated prognostic tools and nominates PVR/CD155 as a tumor cell-intrinsic EMT-associated target candidate for gastric cancer. Stromal or immune regulatory roles of PVR remain plausible but require direct compartment-specific and functional validation.

  • Open Access

    Mechanistic Insights into the FOXM1/BUB1 axis-Mediated Oncogenic Signaling in Hepatocellular Carcinoma

    by Shuping Wang, Yudong Mao, Tingyu Zeng, Tao Yong, Yu An, Jipin Li, Yuan Wang, Xiaojun Yang, Quanlin Guan

    The development of novel therapeutic strategies for advanced and metastatic hepatocellular carcinoma (HCC) remains an urgent clinical need. Despite suboptimal efficacy, the breakthrough of tyrosine kinase inhibitors in HCC treatment therapy underscores the advantage of targeted therapy. Therefore, innovative targeted therapies are urgently needed to enhance treatment efficacy, decrease recurrence rates, and improve patient survival outcomes. The forkhead box M1 (FOXM1) transcription factor serves as a master regulator of oncogenic signaling networks that drive cancer progression. Our study identified budding uninhibited by benzimidazoles 1 (BUB1) as a crucial downstream effector of FOXM1, with demonstrated direct protein-protein interaction. Moreover, FOXM1 directly bound to the GTAAACC motif at the -293 bp region of the BUB1 promoter and activated its transcription, thereby driving HCC cell proliferation. Mechanism studies have shown that the FOXM1/BUB1 axis regulated multiple oncogenic processes in HCC, including cell proliferation, DNA repair, G2/M cell cycle transition, stemness, invasion, and migration. Knockdown of BUB1 significantly sensitized HCC cells and xenograft tumors to the FOXM1 inhibitor FDI-6. Furthermore, combined pharmacological inhibition of FOXM1 (FDI-6, RCM-1, thiostrepton) and BUB1 (BAY-1816032) synergistically inhibited the proliferation of HCC cells and xenograft tumors. These findings establish FOXM1-mediated BUB1 upregulation as a key driver of HCC malignancy. Targeting the FOXM1/BUB1 axis represents a promising therapeutic strategy for the treatment of advanced and metastatic HCC, offering new opportunities for HCC therapy.

  • The rules of different B cell subtypes in colorectal cancer: friends or foes?

    by Yuanchao Shi, Qianwen Luo, Jingwei Duan, Bo Tang, Quanlin Guan

    Tumor-infiltrating B cells (TIBs) are the most important cell type involved in the immune response. TIBs display considerable intratumor heterogeneity due to genetic variation, epigenetic differences and transcriptional plasticity in the tumor microenvironment (TME). Owing to the unique anatomical location of CRC, the B cell subpopulation exhibits more extensive heterogeneity. Many studies have shown that TIBs have gradually become a key predictor of immunotherapy for malignant cancers, including CRC. TIBs have essential functions, including antigen presentation and antibody secretion, and they promote T-cell activation and myeloid chemotaxis. However, owing to the complex TME, TIBs not only promote the antitumor immune response but also inhibit the immune response. With the in-depth study of tumor-infiltrating T cells, tumor-associated myeloid cells and the interactions among these cells in the TME, the special role of immune cells in the TME has gradually become clear. However, the influence of TIBs in the TME and their interactions with nonimmune cells in the TME remain unclear. Here, we summarize the current progress in TIBs based on single-cell RNA sequencing in CRC in recent years, focusing on specific effector or regulatory characteristics of different B cell subclusters in the CRC TME.


  • Pan-cancer investigation regarding the prognostic predictive and immunological regulation functions of PGK1 and experimental validation in esophageal squamous cell carcinoma

    by Junru Chen, Xun Wu, Hongtao Luo, Dandan Wang, Meng Dong, Yuhang Wang, Yuhong Ou, Shilong Sun, Zhiqiang Liu, Qiuning Zhang, et al.

    Phosphoglycerate kinase 1 (PGK1), a pivotal enzyme in the glycolysis pathway, contributes to tumor progression through diverse biological activities like cell metabolism, angiogenesis, proliferation, and epithelial-mesenchymal transformation (EMT). Although PGK1 has been intensively researched in specific cancer types, its overarching significance in pan-cancer contexts remains underexplored. This study leveraged various public database resources, including the Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Tumor Immune Estimation Resource (TIMER2.0), and cBioPortal, to analyze the gene expression, gene alteration characteristics, prognostic value, subcellular localization, biological function, immune characteristics, and drug sensitivity of PGK1 in 33 different cancer types. R software was used to visualize these data. Furthermore, the effects of PGK1 on the proliferation, apoptosis, migration, and invasion of esophageal squamous cell carcinoma (ESCC) cells were also examined in vitro using 5-ethynyl-2′-deoxyuridine (EdU) incorporation assay, CCK-8 assay, Annexin V-FITC/PI assay, migration assay, and invasion assay. The findings suggested that PGK1 is upregulated in various cancer types and closely associated with poor prognosis. In terms of functional enrichment analysis, PGK1 primarily plays a role in glycolysis, hypoxia, EMT, and immune-related pathways. Furthermore, PGK1 is highly expressed in immune and malignant cells in the tumor microenvironment. Notably, PGK1 expression varied significantly among immune cells with distinct activation states. The results of experiments in vitro showed that PGK1 was significantly upregulated in ESCC cells, and its knockdown led to significant inhibition of proliferation, migration, and invasion while increasing cell apoptosis; conversely, overexpression promoted proliferation, migration, and invasion while reducing apoptosis. PGK1 can serve as a prognostic biomarker and therapy target for various cancers, and it may be a promising focal point of immunological studies.


  • Open Access

    Multi-omics reveals that ST6GAL1 promotes colorectal cancer progression through LGALS3BP sialylation

    by Yuanchao Shi, Zhenzhong Pan, Jingwei Duan, Zexing Wang, Yiliang Fang, Bo Tang, Quanlin Guan

    ST6 β-galactoside α2,6-sialyltransferase 1 (ST6GAL1), a crucial enzyme for tumor-associated sialic acid modification, has been reported to positively correlate with colorectal cancer (CRC) tumorigenesis; however, the underlying mechanism remains unclear. To elucidate the protumor mechanisms of ST6GAL1, we performed transcriptomic and N-glycoproteomic analyses and in vitro assays. We found that ST6GAL1 was significantly upregulated in tumor samples than in matched normal samples by analyzing fresh clinical samples from public databases (mean mRNA expression level: tumor vs. normal samples = 0.002712:0.000966, P < 0.05, n = 22). The in vitro results revealed that ST6GAL1 overexpression promoted CRC cell proliferation, migration, and chemoresistance, which were significantly blocked by its knockdown. Transcriptomic data showed that many genes related to the four modules (proliferation/cell cycle, migration, motility, and epithelial–mesenchymal transition (EMT) were upregulated after ST6GAL1 overexpression but downregulated after ST6GAL1 knockdown. Furthermore, the N-glycoproteomic data revealed that 25 substrates that were sialylated upon ST6GAL1 overexpression were related to protumor activity. Importantly, we found that knockdown of lectin galactoside-binding soluble 3-binding protein (LGALS3BP), a newly identified secreted substrate of ST6GAL1, significantly blocked the proliferation, invasion, and chemoresistance of CRC cells induced by ST6GAL1 overexpression. Treatment with sialidases (neuraminidases, NAs) also blocked the protumor activity of ST6GAL1. Thus, ST6GAL1-induced increased sialylation of substrates, such as LGALS3BP and upregulation of protumor genes promote CRC tumorigenesis and chemoresistance, which provides important perspectives and new targets for the treatment of CRC.


  • Open Access

    Comprehensive Analysis of scRNA-Seq and Bulk RNA-Seq Identified TIMP1 as a Prognostic Marker in Colorectal Cancer

    by Qian-Wen Luo, Yuan-Chao Shi, Wang-Qiang Jia, Xiao-Hai Zhou, Zheng-Rong Yang, Yan Wang, Quan-Lin Guan

    Luo QW, et al. Immune Netw. 2025 Oct;25(5):e38. https://doi.org/10.4110/in.2025.25.e38


  • Pan-cancer analysis of NADPH oxidase 4 identifying its prognostic and immunotherapy predictive value and in vitro experimental verification in glioblastoma

    by Xun Wu, Junru Chen, Hongtao Luo, Tianqi Du, Qian Wang, Mingyu Tan, Yanliang Chen, Shilong Sun, Zhiqiang Liu, Zhen Yang, et al.


  • Open Access

    Targeting neutrophil elastase is a promising direction for future cancer treatment

    by Wangqiang Jia, Yudong Mao, Qianwen Luo, Jiang Wu, Quanlin Guan

    Neutrophil elastase (NE) is a proteolytic enzyme released extracellular during the formation of neutrophil extracellular traps (NETs) through degranulation. In addition to participating in the body's inflammatory response, NE also plays an important role in cancer. It can promote tumor proliferation, migration, and invasion, induce epithelial-mesenchymal transition (EMT), and change the tumor microenvironment (TME) to promote tumor progression. Concurrently, NE promotes systemic treatment resistance by inducing EMT. However, it can also selectively kill cancer cells and attenuate tumor development. Sivelestat is a specific NE inhibitor that can be used in the perioperative period of esophageal cancer patients to reduce the incidence of postoperative complications after esophagectomy. In addition, the combination of sivelestat and trastuzumab can enhance the efficacy of human epidermal growth factor receptor 2(HER 2) positive breast cancer patients. Meanwhile, targeting the human antibody domains and fragments of NE is also a new way to treat cancer and inflammation-related diseases. This review provides valuable insights into the role of NE in cancer treatment. Additionally, we discuss the challenges associated with the clinical application of sivelestat. By shedding light on the promising potential of NE, this review contributes to the advancement of cancer treatment strategies.